HC Wainwright & Co. Reiterates Buy on MediWound, Maintains $28 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterated a Buy rating on MediWound (NASDAQ:MDWD) and maintained a $28 price target.
March 22, 2024 | 10:18 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. reaffirmed a Buy rating on MediWound, with a steady price target of $28, indicating a positive outlook on the stock.
The reiteration of a Buy rating and maintenance of a $28 price target by a reputable analyst firm like HC Wainwright & Co. suggests a strong belief in MediWound's potential for growth. This positive outlook is likely to influence investor sentiment and could lead to a short-term increase in MDWD's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100